NASDAQ:ZSANZosano Pharma Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Zosano Pharma Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.82 -0.01 (-1.20 %) (As of 07/10/2020 04:00 PM ET) Add Compare Share Today's Range$0.80Now: $0.82▼$0.8350-Day Range$0.81MA: $0.89▼$1.1052-Week Range$0.41Now: $0.82▼$3.52Volume985,800 shsAverage Volume1.00 million shsMarket Capitalization$44.56 millionP/E RatioN/ADividend YieldN/ABeta2.71 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingZosano Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.75, Zosano Pharma has a potential upside of 479.3% from its current price of $0.82.Amount of Analyst CoverageZosano Pharma has only been the subject of 2 research reports in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesZosano Pharma has received 299 “outperform” votes. (Add your “outperform” vote.)Underperform VotesZosano Pharma has received 221 “underperform” votes. (Add your “underperform” vote.)Community SentimentZosano Pharma has received 57.50% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Zosano Pharma and other stocks. Vote “Outperform” if you believe ZSAN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ZSAN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldZosano Pharma does not currently pay a dividend.Dividend GrowthZosano Pharma does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zosano Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.10% of the stock of Zosano Pharma is held by insiders.Percentage Held by InstitutionsOnly 17.05% of the stock of Zosano Pharma is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Zosano Pharma are expected to grow in the coming year, from ($0.50) to ($0.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zosano Pharma is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zosano Pharma is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZosano Pharma has a P/B Ratio of 2.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.41 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ZSAN Previous Symbol CUSIPN/A CIK1587221 Webwww.zosanopharma.com Phone510-745-1200Debt Debt-to-Equity Ratio0.23 Current Ratio0.93 Quick Ratio0.93Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.40 per share Price / Book2.05Profitability EPS (Most Recent Fiscal Year)($2.29) Net Income$-37,590,000.00 Net MarginsN/A Return on Equity-234.92% Return on Assets-84.01%Miscellaneous Employees53 Outstanding Shares54,340,000Market Cap$44.56 million Next Earnings Date8/12/2020 (Estimated) OptionableNot Optionable NASDAQ:ZSAN Rates by TradingView Receive ZSAN News and Ratings via Email Sign-up to receive the latest news and ratings for ZSAN and its competitors with MarketBeat's FREE daily newsletter. Zosano Pharma (NASDAQ:ZSAN) Frequently Asked Questions How has Zosano Pharma's stock been impacted by COVID-19 (Coronavirus)? Zosano Pharma's stock was trading at $0.5662 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ZSAN stock has increased by 44.8% and is now trading at $0.82. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Zosano Pharma? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zosano Pharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Zosano Pharma. When is Zosano Pharma's next earnings date? Zosano Pharma is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Zosano Pharma. How were Zosano Pharma's earnings last quarter? Zosano Pharma Corp (NASDAQ:ZSAN) announced its earnings results on Thursday, May, 14th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.28) by $0.04. View Zosano Pharma's earnings history. When did Zosano Pharma's stock split? How did Zosano Pharma's stock split work? Shares of Zosano Pharma reverse split before market open on Friday, January 26th 2018. The 1-20 reverse split was announced on Thursday, January 25th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 25th 2018. An investor that had 100 shares of Zosano Pharma stock prior to the reverse split would have 5 shares after the split. What price target have analysts set for ZSAN? 4 Wall Street analysts have issued 12 month price targets for Zosano Pharma's stock. Their forecasts range from $2.00 to $7.00. On average, they expect Zosano Pharma's stock price to reach $4.75 in the next twelve months. This suggests a possible upside of 479.3% from the stock's current price. View analysts' price targets for Zosano Pharma. Has Zosano Pharma been receiving favorable news coverage? News articles about ZSAN stock have been trending very negative on Sunday, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Zosano Pharma earned a news sentiment score of -3.8 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Zosano Pharma. Who are some of Zosano Pharma's key competitors? Some companies that are related to Zosano Pharma include Galera Therapeutics (GRTX), Aravive (ARAV), Theratechnologies (THTX), GlycoMimetics (GLYC), NuCana (NCNA), Trevena (TRVN), Sol Gel Technologies (SLGL), Aytu Bioscience (AYTU), Avenue Therapeutics (ATXI), Scpharmaceuticals (SCPH), Galectin Therapeutics (GALT), Cerecor (CERC), Evofem Biosciences (EVFM), Kindred Biosciences (KIN) and Tyme Technologies (TYME). View all competitors. What other stocks do shareholders of Zosano Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zosano Pharma investors own include Amplify Energy (AMPY), Amplify Energy (AMPY), AEterna Zentaris (AEZS), Titan Pharmaceuticals (TTNP), Ekso Bionics (EKSO), Hallador Energy (HNRG), Miragen Therapeutics (MGEN), ADMA Biologics (ADMA), BioNano Genomics (BNGO) and Matinas BioPharma (MTNB). Who are Zosano Pharma's key executives? Zosano Pharma's management team includes the following people: Mr. John P. Walker, Chairman, CEO & Pres (Age 70)Ms. Hayley Lewis, Sr. VP of Operations (Age 43)Dr. Donald J. Kellerman, VP of Clinical Devel. & Medical Affairs (Age 64)Mr. Greg Kitchener, Chief Financial Officer (Age 48)Jeffrey L. Quillen, Sec. When did Zosano Pharma IPO? (ZSAN) raised $47 million in an IPO on Tuesday, January 27th 2015. The company issued 4,300,000 shares at $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners acted as the underwriters for the IPO. What is Zosano Pharma's stock symbol? Zosano Pharma trades on the NASDAQ under the ticker symbol "ZSAN." How do I buy shares of Zosano Pharma? Shares of ZSAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Zosano Pharma's stock price today? One share of ZSAN stock can currently be purchased for approximately $0.82. How big of a company is Zosano Pharma? Zosano Pharma has a market capitalization of $44.56 million. The biotechnology company earns $-37,590,000.00 in net income (profit) each year or ($2.29) on an earnings per share basis. Zosano Pharma employs 53 workers across the globe. What is Zosano Pharma's official website? The official website for Zosano Pharma is www.zosanopharma.com. How can I contact Zosano Pharma? Zosano Pharma's mailing address is 34790 ARDENTECH COURT, FREMONT CA, 94555. The biotechnology company can be reached via phone at 510-745-1200 or via email at [email protected] This page was last updated on 7/12/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
